Micronomicin (sulfate)
(Synonyms: 硫酸小诺霉素; Gentamicin C2b sulfate; Antibiotic XK-62-2 sulfate; Sagamicin sulfate) 目录号 : GC45514
An aminoglycoside antibiotic
Cas No.:66803-19-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Micronomicin is an aminoglycoside antibiotic originally isolated from Micromonospora.1,2 It is active against S. aureus, B. subtilis, B. cereus, E. coli, and K. pneumoniae (MICs = 0.001-8.3 μg/ml) and inactive against C. albicans and A. niger (MICs = >10 μg/ml).1
References
1. Okachi, R., Kawamoto, I., Takasawa, S., et al. A new antibiotic XK-62-2 (Sagamicin). I. Isolation, physicochemical and antibacterial properties. J. Antibiot. (Tokyo) 27(10), 793-800 (1974).
2. Eagan, R.S., DeVault, R.L., Mueller, S.L., et al. A new antibiotic XK-62-2. III The structure of XK-62-2, a new gentamicin C complex antibiotic. J. Antibiot. (Tokyo) 28(1), 29-34 (1975).
| Cas No. | 66803-19-8 | SDF | |
| 别名 | 硫酸小诺霉素; Gentamicin C2b sulfate; Antibiotic XK-62-2 sulfate; Sagamicin sulfate | ||
| Canonical SMILES | [H][C@@]1(OC[C@@](O)(C)[C@H](NC)[C@H]1O)O[C@H]([C@H]2O)[C@H](N)C[C@H](N)[C@H]2O[C@@]3([H])O[C@H](CNC)CC[C@H]3N.O=S(O)(O)=O | ||
| 分子式 | C20H41N5O7.XH2SO4 | 分子量 | 463.6 |
| 溶解度 | DMF: ,DMSO: ,Ethanol: Partially soluble,PBS (pH 7.2): 2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.157 mL | 10.7852 mL | 21.5703 mL |
| 5 mM | 0.4314 mL | 2.157 mL | 4.3141 mL |
| 10 mM | 0.2157 mL | 1.0785 mL | 2.157 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Impurity profiling of Micronomicin sulfate injection by liquid chromatography-ion trap mass spectrometry
J Pharm Biomed Anal 2013 Mar 5;75:94-104.PMID:23261805DOI:10.1016/j.jpba.2012.11.029.
The characterization of impurities present in Micronomicin sulfate injection by liquid chromatography (LC) coupled with mass spectrometry (MS) is described. A reversed phase (RP)-LC method using a C₁₈ column resistant to an alkaline (pH 11) aqueous mobile phase was developed and coupled to MS with an electrospray ionization (ESI) source in the positive ion mode which provides MS(n) capability. A total of thirty six impurities were detected in commercial samples: five impurities were identified by comparison of their fragmentation patterns with those of available related substances, eleven of them were identified in accordance with relevant literature, while the other twenty impurities were newly identified using the MS/MS spectra of the available related reference substances as interpretative templates combined with knowledge of the nature of functional group fragmentation behaviors. This work was applied to evaluate the quality of Micronomicin sulfate injection from different manufacturers.
Analysis of Micronomicin by liquid chromatography with pulsed electrochemical detection
J Chromatogr A 2013 Jun 21;1295:90-8.PMID:23683397DOI:10.1016/j.chroma.2013.04.059.
This paper describes the separation of the main component Micronomicin from its related substances using a new established liquid chromatographic method with pulsed electrochemical detection (LC-PED). The mobile phase consists of 1 volume of acetonitrile and 99 volumes of an aqueous solution containing 1.25% (v/v) trifluoroacetic acid, 0.025% (v/v) pentafluoropropionic acid and 0.85% (v/v) of 50% sodium hydroxide. The pH of the aqueous solution is adjusted to 2.6 with 0.5 M NaOH. The influence of the different chromatographic parameters on the separation was investigated. A quadruple-potential waveform was used as detection waveform. 0.5 M NaOH was added post column at a flow rate of 0.3 mL/min to raise the pH of detection to at least 12. The LOD and LOQ of Micronomicin are 0.08 μg/mL (1.6 ng injected) and 0.25 μg/mL (5 ng injected), respectively. The linearity of Micronomicin ranges from 0.25 to 60 μg/mL with a correlation coefficient of 0.9978. Intra-day RSD and inter-day RSD of Micronomicin are 0.89% and 0.55%, respectively. This method proved to be robust and is also applicable to a wider number of C18 columns. A number of commercial samples of Micronomicin sulfate were analyzed using this method and 18 peaks can be separated from the main component and from each other in one sample. Seven peaks could be identified using reference substances. The chemical structure of two unknown impurities could be characterized by LC-MS based on comparison of their fragmentation patterns with those of available reference substances.
[Ototoxicity of Micronomicin sulfate--audiometric assessment]
Jpn J Antibiot 1983 Oct;36(10):2921-4.PMID:6674525doi
Micronomicin sulfate (MCR) is a new aminoglycoside antibiotic, and its antibacterial spectrum is similar to that of gentamicin (GM). According to the animal test, MCR has less ototoxicity than other aminoglycoside antibiotics such as GM. To check its clinical ototoxicity, MCR was given intramuscularly to 20 patients at dose of 120--240 mg/day, respectively for 2--8 days, and audiometry was carried out before and after administration of MCR. No evident change was detected between the preadministration hearing levels and the postadministration hearing levels. These data suggest that MCR is sufficiently safe in ototoxicity within dose of 120 mg/day for 4 days.
Neuromuscular blocking actions of the aminoglycoside antibiotics sisomicin and Micronomicin in the rabbit
Tohoku J Exp Med 1997 Apr;181(4):471-3.PMID:9210254DOI:10.1620/tjem.181.471.
The neuromuscular blocking actions of sisomicin sulfate (SISO), Micronomicin sulfate (MCR) and d-tubocurarine (dTc) were studied in 20 rabbits anesthetized with halothane. The i.v. administration of SISO 20-40 mg/kg, MCR 40-80 mg/kg or dTc 0.1-0.3 mg/kg resulted in dose-dependent decreases in twitch tension. The ED50s for SISO, MCR and dTc were 23.5, 58.2 and 0.2 mg/kg, respectively. SISO- and MCR-induced neuromuscular blockade was partially antagonized by neostigmine or by calcium.
[Determination of the content for Micronomicin sulfate by ultraviolet spectrophotometric derivatization]
Hunan Yi Ke Da Xue Xue Bao 1997;22(4):363-5.PMID:9868100doi
An ultraviolet spectrophotometric method for determination of micromonicin (MCR) was developed by the reaction of MCR with o-pathaldehyde (OPA) and obtained a derivative absorbing ultraviolet in special wave length. The comparison was made between this method and high performance liquid chromatography (HPLC). The results indicate that the method is simple, rapid, precise and reproducible.